Halozyme Therapeutics, Inc., announced a global collaboration and non-exclusive license agreement with Acumen Pharmaceuticals that provides Acumen access to Halozyme’s ENHANZE drug delivery technology, a proprietary recombinant human hyaluronidase PH20 enzyme (rHuPH20) for rapid subcutaneous drug delivery, for a single target. Acumen intends to explore the potential use of ENHANZE® for ACU193, Acumen’s clinical-stage monoclonal antibody (mAb) candidate to target Amyloid-β Oligomers (AβOs) for the treatment of early Alzheimer’s disease (AD).
Under the terms of the agreement, Acumen will make an upfront payment to Halozyme, and potential future milestone payments related to development progress, regulatory approvals, and sales attainment. Halozyme will also be entitled to single digit royalties on net sales of commercialized medicines with the ENHANZE technology.
This partnership presents an exceptional opportunity to provide additional treatment options to patients with Alzheimer’s disease. According to the World Health Organization, over 55 million people suffer from dementia worldwide, and Alzheimer’s disease can be attributed to 60-70% of cases.
Also Read : City of Everett offers improved healthcare experience for all employees through Vera Whole Health
Acumen reported positive Phase 1 results that demonstrated ACU193 was generally well-tolerated with a compelling overall safety profile, meeting the primary objective of its first-in-human, randomized, double-blind, placebo-controlled study in both single and multiple doses in patients with early AD. ACU193 has been granted Fast Track designation for the treatment of early Alzheimer’s disease by the U.S. Food and Drug Administration.
“Our collaboration with Acumen for ENHANZE reinforces our commitment to provide innovative solutions to improve the patient treatment experience, particularly for such a challenging disease in a large patient population,” said Dr. Helen Torley, president and chief executive officer. “We share Acumen’s view that the Alzheimer’s disease treatment paradigm is at a key inflection point with recent and expected approvals paving a new path for treatment. We appreciate the opportunity to enter this market and look forward to supporting the development of ACU193 to emerge as a potential treatment of choice.”
SOURCE : PRNewswire